Vaxcyte (PCVX) Current Leases (2019 - 2026)

Vaxcyte (PCVX) has reported Current Leases for 7 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Leases fell 0.7% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (down 0.7% YoY), while the FY2025 annual figure was $6.1 million, up 3.96% from the prior year.
• Current Leases slipped to $6.1 million in Q1 2026 per PCVX's latest filing, from $6.1 million in the prior quarter.
• Across five years, Current Leases topped out at $9.6 million in Q3 2024 and bottomed at $5.8 million in Q3 2025.
• Historically, Current Leases has averaged $6.5 million across 5 years, with a median of $6.1 million in 2025.
• Annual changes were most pronounced in 2022 — Current Leases soared 948.29% — and 2025, when it slumped 40.12%.
• Vaxcyte's Current Leases stood at $5.9 million in 2022, then increased by 20.36% to $7.1 million in 2023, then fell by 17.18% to $5.9 million in 2024, then advanced by 3.96% to $6.1 million in 2025, then declined by 0.64% to $6.1 million in 2026.
• Business Quant data shows PCVX's Current Leases at $6.1 million in Q1 2026, $6.1 million in Q4 2025, and $5.8 million in Q3 2025.